EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors

This publication has 76 references indexed in Scilit:

• Key cancer cell signal transduction pathways as therapeutic targets
  European Journal Of Cancer, 2006
• Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
  JNCI Journal of the National Cancer Institute, 2005
• Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
  Journal of Clinical Oncology, 2005
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLoS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor
  Published by Elsevier ,2002
• Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
  The EMBO Journal, 2002
• Mandibular Reconstruction Using a Vascularized Osteocutaneous Scapular Flap.
  Nippon Jibiinkoka Gakkai Kaiho, 1994